LFNG is a differentially expressed gene in human metastatic breast cancer, in the brain and in the lymph nodes.

Shahan Mamoor, MS¹
¹shahanmamoor@gmail.com
East Islip, NY USA

Metastasis to the brain is a clinical problem in patients with breast cancer¹⁻³. We mined published microarray data^{4,5} to compare primary and metastatic tumor transcriptomes for the discovery of genes associated with brain metastasis in humans with metastatic breast cancer. We found that O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase, encoded by LFNG, was among the genes whose expression was most different in the brain and lymph node metastases of patients with metastatic breast cancer. LFNG mRNA was present at increased quantities in brain metastatic tissues as compared to primary tumors of the breast. Importantly, expression of LFNG in primary tumors was significantly correlated with patient recurrence-free survival in patients with breast cancer. Modulation of LFNG expression may be relevant to the biology by which tumor cells metastasize from the breast to the brain while evading immune clearance in the lymph nodes in humans with metastatic breast cancer. These data are one piece of evidence suggesting a common ancestor or tumor clone for brain and lymph node metastases that originate from the primary tumor, alluding to patterns in developmental origin and migratory pathways through the lymph node in human brain metastatic breast cancer.

Keywords: breast cancer, metastasis, brain metastases, central nervous system metastases, lymph node metastases, O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase, LFNG, systems biology of breast cancer, targeted therapeutics in breast cancer.

One report described a 34% incidence of central nervous system metastases in patients treated with trastuzumab for breast cancer². More recently, the NEfERT-T clinical trial⁶ which compared administration of either neratinib or trastuzumab in conjunction with paclitaxel demonstrated that in a randomized, controlled setting, in breast cancer patients treated with neratinib, not only was the incidence of central nervous system recurrence significantly lower, the time to central nervous system metastasis was significantly delayed as compared to patients administered trastuzumab⁶. The alarmingly high rate of central nervous system metastasis described, as well as data, both anecdotal² and from a randomized, controlled setting⁶ illustrating that treatment with trastuzumab may be associated with these events demands an enhanced understanding of the transcriptional makeup of brain metastatic tissues to support identification of therapeutic targets, whether they are treatment related or not. We performed a global comparative analysis of primary and metastatic tumors in patients with brain metastatic breast cancer^{4,5}. We discovered differential and increased expression of the gene encoding O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase, LFNG, in brain metastatic tissues of patients with metastatic breast cancer.

Methods

We used datasets GSE10893⁴ and GSE124648⁵ for this global differential gene expression analysis of brain metastatic breast cancer in conjunction with GEO2R. GSE10893 was generated using Agilent-011521 Human 1A Microarray G4110A technology with $n=11$ primary breast tumors and $n=3$ brain metastases from patients with breast cancer; analysis was performed using platform GPL885. GSE124648 was generated using Affymetrix Human Genome U133A array technology with $n=10$ normal breast tissues and $n=44$ lymph node metastases from patients with breast cancer; analysis was performed using platform GPL96. The Benjamini and Hochberg method of p -value adjustment was used for ranking of differential expression but raw p -values were used to assess statistical significance of global differential expression. Log-transformation of data was auto-detected, and the NCBI generated category of platform annotation was used. A statistical test was performed to evaluate whether LFNG gene expression was significantly different between primary tumors of the breast and brain metastases in humans with breast cancer using a two-tailed t-test. For Kaplan-Meier survival analysis, we used the Kaplan-Meier plotter online tool⁷ for correlation of LFNG mRNA expression levels in primary tumors of the breast with recurrence-free survival in $n=3951$ breast cancer patients.

Results

We performed global comparative transcriptome analysis of metastatic and primary tumor tissues of patients with metastatic breast, as well as normal tissues of the breast using published microarray data^{4,5} to describe the transcriptional landscape of brain metastasis in human breast cancer in an unbiased fashion and for the discovery of novel therapeutic targets.

LFNG is differentially expressed in the brain metastases of patients with brain metastatic breast cancer.

Through blind, systems-level analysis of published microarray data⁴, we identified O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase, encoded by LFNG, as a differentially expressed gene in the brain metastatic tissues of humans with breast cancer (Table 1). When

1 sorting each of the genes expressed in brain metastases based on significance of difference as
2 compared to primary tumors of the breast in patients with breast cancer, LFNG ranked 128 out of
3 17418 total transcripts (Chart 1), equating to 99.3% differential expression. Differential
4 expression of LFNG in the brain metastases of patients with metastatic breast cancer was
statistically significant (Chart 1; $p=4.34E-04$).

5 **LFNG is differentially expressed in the lymph node metastases of patients with breast** 6 **cancer.**

7 To determine whether differential expression of LFNG in human breast cancer could be
8 validated in a second microarray dataset, and whether this was specific to brain metastases or
9 could be observed in other anatomical locations, we queried a second microarray dataset⁵, here
10 comparing normal breast tissues to lymph node metastases. Again, we identified LFNG as a
11 differentially expressed gene in the lymph node metastatic tissues of patients with breast cancer
12 (Chart 2). When sorting each of the genes expressed in lymph node metastases based on
13 significance of difference as compared to normal breast tissues, LFNG ranked 4152 out of 22283
total transcripts (Chart 2), equating to 81.4% differential expression. Differential expression of
LFNG in the lymph node metastases of patients with metastatic breast cancer was statistically
significant (Chart 2; $p=2.86e-03$). Thus, differential expression of LFNG, transcriptome-wide, in
metastatic tissues of women with metastatic breast cancer was conserved across two independent
microarray datasets, in the brain and in the lymph nodes.

14 **LFNG is expressed at higher levels in the brain metastases of patients with metastatic** 15 **breast cancer.**

16 We obtained exact mRNA expression levels for LFNG, in primary tumors of the breast and
17 in brain metastasis of patients with brain metastatic breast cancer to determine direction and
18 statistical significance of change in LFNG expression in brain metastatic tissues. We observed
19 significantly higher expression of LFNG in the brain metastases of patients with breast cancer as
20 compared to primary tumors of the breast: LFNG was expressed at 1.39 ± 0.95 arbitrary units
(AU) in primary tumors of the breast, while it was expressed at 3.82 ± 0.53 AU in brain
metastatic tissues (Figure 1). The difference in LFNG mRNA levels between primary tumors of
the breast and brain metastatic tissues was statistically significant (Figure 1; $p=0.00132$).

21 **LFNG expression is correlated with survival outcomes in human breast cancer.**

22 We performed Kaplan-Meier survival analysis⁷ in 3951 breast cancer patients in total, to
23 evaluate whether LFNG tumor expression was correlated with survival outcomes in breast cancer.
24 We observed a correlation between primary tumor expression of LFNG and recurrence-free
25 survival (RFS) in patients with breast cancer (Figure 2). Patients whose primary tumors
26 expressed low levels of LFNG possessed median RFS of 191.21 months, while patients whose
27 tumors expressed high levels of LFNG possessed median RFS of 216.66 months. This difference
28 in RFS based on LFNG tumor expression in patients with breast cancer was statistically
significant (Figure 2, Chart 3; logrank p -value $4.8e-5$; hazard ratio: 0.8 (0.72-0.89)).

Thus, by mining published microarray data^{4,5} in an unbiased and systematic fashion, we identified O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase, encoded by LFNG, as among the genes whose expression was most different, transcriptome-wide, in the brain and lymph node metastases of patients with breast cancer, when compared to primary tumors of the breast and to normal breast tissues, respectively; we observed significantly increased expression of LFNG in brain metastases as compared to primary tumors of the breast. Further, we found a correlation between LFNG expression and patient survival outcomes, as recurrence-free survival was greater in patients whose primary tumors expressed higher levels of LFNG as compared to patients whose primary tumors expressed lower levels of LFNG.

Discussion

We provided evidence here that LFNG is among the genes whose expression is most different in the brain and lymph node metastases of patients with metastatic breast cancer, that LFNG mRNA is present at significantly increased quantity in brain metastatic tissues as compared to primary tumors of the breast, and that primary tumor LFNG expression is significantly correlated with patient survival outcomes in human breast cancer. Evaluation of the effects of genetic depletion of LFNG in mouse models of metastatic breast cancer on metastasis to the central nervous system is merited. Modulation of LFNG expression may be relevant to the processes by which breast cancer cells exit the breast, enter the vasculature and/or lymphatics, reside in the lymph nodes, evade immune clearance, breach the blood-brain barrier and colonize the brain. These data are one piece of evidence that allude to a common cell or cell(s) of origin for brain and lymph node metastases in human metastatic breast cancer.

References

1. Lin, N.U., Amiri-Kordestani, L., Palmieri, D., Liewehr, D.J. and Steeg, P.S., 2013. CNS metastases in breast cancer: old challenge, new frontiers.
2. Bendell, J.C., Domchek, S.M., Burstein, H.J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R. and Winer, E., 2003. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. *Cancer*, 97(12), pp.2972-2977.
3. Tsukada, Y., Fouad, A., Pickren, J.W. and Lane, W.W., 1983. Central nervous system metastasis from breast carcinoma autopsy study. *Cancer*, 52(12), pp.2349-2354.
4. Weigman, V.J., Chao, H.H., Shabalin, A.A., He, X., Parker, J.S., Nordgard, S.H., Grushko, T., Huo, D., Nwachukwu, C., Nobel, A. and Kristensen, V.N., 2012. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. *Breast cancer research and treatment*, 133(3), pp.865-880.
5. Sinn, B.V., Fu, C., Lau, R., Litton, J., Tsai, T.H., Murthy, R., Tam, A., Andreopoulou, E., Gong, Y., Murthy, R. and Gould, R., 2019. SET ER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. *NPJ breast cancer*, 5(1), pp.1-8.
6. Awada, A., Colomer, R., Inoue, K., Bondarenko, I., Badwe, R.A., Demetriou, G., Lee, S.C., Mehta, A.O., Kim, S.B., Bachelot, T. and Goswami, C., 2016. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. *JAMA oncology*, 2(12), pp.1557-1564.
7. Györfy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q. and Szallasi, Z., 2010. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast cancer research and treatment*, 123(3), pp.725-731.

Rank: 128
Probe ID: 8736
p-value: 4.34E-04
t: -4.51
B: 0.2028
Gene: LFNG
Gene name: O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase

Chart 1: LFNG is differentially expressed in brain metastatic breast cancer when comparing brain metastases to primary tumors of the breast.

The rank of global differential expression, the probe/transcript ID, the *p*-value with respect to differential expression transcriptome-wide, *t*, a moderated t-statistic, *B*, the log-odds of differential expression between the groups compared, the gene and gene name are listed in this chart.

Rank: 4152
probe ID: 215270_at
p-value: 2.86e-03
t: 3.120459
B: -2.44517
Gene: LFNG
Gene name: O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase

Chart 2: LFNG is differentially expressed in the lymph node metastases of patients with breast cancer when comparing lymph node metastases to normal breast tissues.

The rank of global differential expression, probe/transcript ID, the *p*-value with respect to differential expression transcriptome-wide, *t*, a moderated *t*-statistic, *B*, the log-odds of differential expression between the groups compared, the gene and gene name are listed in this chart.

Figure 1: LFNG is expressed at significantly higher levels in the brain metastases of patients with metastatic breast cancer when compared to primary tumors of the breast.

The mRNA expression level of LFNG in primary tumors of the breast (left) and in brain metastases of women with metastatic breast cancer (right) is graphically depicted; the result of a statistical test evaluating significance of difference in LFNG expression between primary tumors and brain metastases is $p=0.00132$.

Figure 2: Significant correlation between LFNG primary tumor expression and recurrence-free survival in patients with breast cancer.

Depicted in this Kaplan-Meier plot is the probability of recurrence-free survival for $n=3951$ total breast cancer patients stratified into two groups, based on low or high expression of LFNG in patient primary tumors. The log rank p -value denoting statistical significance of difference in recurrence-free survival when comparing the two groups, as well as hazard ratio for this comparison is listed above. Listed below is the number of patients at risk (number of patients alive) per interval, after stratification based on LFNG expression; in the first interval, number at risk is number of patients alive; in each subsequent interval, number at risk is the number at risk less those who have expired or are censored.

Low LFNG expression: 191.21 months

High LFNG expression: 216.66 months

Chart 3: Median recurrence-free survival is inferior in patients with low primary tumor expression of LFNG.

The median RFS (recurrence-free survival) of patients with low primary tumor expression of LFNG and high primary tumor expression of LFNG is listed in this chart, for $n=3951$ breast cancer patients.